A Clinical Study of Lyophilized Plasma in Patients on Warfarin
Phase 2
Withdrawn
- Conditions
- Anticoagulant Therapy
- Registration Number
- NCT01541098
- Lead Sponsor
- HemCon Medical Technologies, Inc
- Brief Summary
This is a multi center, phase 2 randomized controlled study to determine the effect of lyophilized plasma in patients on warfarin therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Assess and Compare Adverse Events Duration of Study (Less than or equal to 72 hours) The primary safety objective is to assess the adverse events after infusion of lyophilized plasma compared to control.
- Secondary Outcome Measures
Name Time Method